Vaccination against measles, mumps, rubella and varicella (MMRV) is currently recommended in developed countries for infants from 12 months of age. However, measles vaccination at 9 months of age is recommended by the WHO in the Expanded Program on Immunization (EPI) schedule and it is therefore possible that MMR or MMRV vaccines might also be given at this age. This open-label, randomised, comparative study evaluated the immunogenicity and safety of a 2-dose schedule of ProQuad(®) (MMRV vaccine) given at a 3-month interval in healthy infants aged ≥9 months. For measles, the non-inferiority of the response rate post-Dose 2 was reached when Dose 1 was administered at 11 months (98%) compared with 12 months (99%) but was not reached when Dose 1 was administered at 9 months (95%). The response rate to measles post-Dose 1 increased with age, from 73% to 88% and 90% at 9, 11 and 12 months, respectively. For mumps, rubella and varicella, response rates were not different after Dose 1 (>95%) or Dose 2 (>99%) regardless of whether Dose 1 was administered at 9, 11 or 12 months of age. In conclusion, the age of administration of the first of a two-dose regimen of ProQuad may be lowered to 11 months. Dose 1 may be administered at 9 months if early protection is required, but it should be recognised that a second dose is required promptly with a minimum of 3-month interval between doses.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.vaccine.2012.02.062 | DOI Listing |
Since treatment with anticoagulants can prevent recurrent strokes, identification of patients at risk for incident AF after stroke is crucial. We aimed to investigate whether the addition of AF polygenic risk scores (PRS) to existing clinical risk predictors could improve prediction of AF after stroke. Patients diagnosed with ischemic stroke at Massachusetts General Hospital between 2003-2017 were included.
View Article and Find Full Text PDFHematology
December 2025
Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People's Republic of China.
Objective: To evaluate the short-term efficacy and safety of eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in China.
Method: Data were retrospectively collected from patients with PNH who received at least 3 months of full-dose eculizumab. Changes in clinical and laboratory indicators after 1, 3, and 6 months of eculizumab therapy and at the end of follow-up were documented.
Eur Stroke J
January 2025
Department of Neurology, University Hospital RWTH Aachen, Aachen, Germany.
Introduction: Distal arterial occlusions can cause measurable changes in the flow wave profile in proximal segments of the feeding artery. Our objective was to study the diagnostic accuracy of point-of-care ultrasound (POCUS) of the common carotid arteries (CCA) for detection of anterior circulation large vessel occlusion (ac-LVO) in patients with suspected stroke.
Patients And Methods: We conducted a prospective, single-center, observational study of adult patients with suspected stroke admitted in the emergency department.
J Brachial Plex Peripher Nerve Inj
January 2025
School of Health Sciences, Manchester Academic Health Science Centre, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom.
GABA (γ-aminobutyric acid) is the major inhibitory neurotransmitter in the brain. In response to injury within the central nervous system, GABA promotes cortical plasticity and represents a potential pharmacological target to improve functional recovery. However, it is unclear how GABA changes in the brain after traumatic brachial plexus injuries (tBPIs) which represents the rationale for this pilot study.
View Article and Find Full Text PDFClin Ophthalmol
January 2025
Department of Ophthalmology, the First Affiliated Hospital with Nanjing Medical University, Nanjing, People's Republic of China.
Purpose: This study aims to validate and revise the Spot Vision Screener referral criteria for detecting amblyopia risk factors (ARFs), visually significant refractive error (VSRE), and amblyopia.
Methods: In clinics, we gathered data from children aged 12 months to 7 years. The validity of the cut-off values was assessed using receiver operating characteristic (ROC) curves, with cycloplegic retinoscopy serving as a reference.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!